MIRM

MIRM is executing a 'High-Conviction Price Discovery' phase, driven by a structural repricing of its growth trajectory rather than speculative hype. The +39.6% monthly surge is anchored by the Jan 12th preliminary revenue beat ($520M vs guidance) and the strategic acquisition of Bluejay Therapeutics (closed Jan 26th), which expanded its rare disease pipeline. In a 'Risk-On' regime where yields are rising, capital is rotating into 'Quality Growth' biotechs with commercialized assets (Livmarli) and visible cash flow, insulating MIRM from broader macro tariff jitters.